Huntsman Cancer Institute: Comprehensive Market Research Report

Background

Overview

Huntsman Cancer Institute (HCI), located in Salt Lake City, Utah, is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center serving Utah, Nevada, Montana, Wyoming, and Idaho. Established in 1999 following a generous donation from Jon M. and Karen Huntsman, HCI is dedicated to understanding cancer from its origins, improving treatments, alleviating patient suffering, and providing education on cancer risk, prevention, and care.

Mission and Vision

HCI's mission is to understand cancer from its beginnings, use that knowledge to create and improve cancer treatments, relieve the suffering of cancer patients, and provide education about cancer risk, prevention, and care. Its vision is to deliver a cancer-free frontier through scientific discovery and human touch.

Primary Area of Focus and Industry Significance

HCI focuses on comprehensive cancer research, patient care, and education. As the only NCI-designated Comprehensive Cancer Center in the Mountain West, it plays a pivotal role in advancing cancer research and treatment, serving a vast geographic region and contributing significantly to the national cancer care landscape.

Key Strategic Focus

Core Objectives

Advance cancer research across basic, translational, and clinical domains.

Provide comprehensive patient care with a team-based approach.

Enhance community education and outreach on cancer prevention and care.

Specific Areas of Specialization

Precision oncology.

Data science and artificial intelligence in cancer research.

Melanoma prevention and care.

Lung cancer and tobacco control.

Cancer prevention and care in rural and frontier populations.

Key Technologies Utilized

Artificial intelligence and data analytics.

Advanced imaging and diagnostic technologies.

State-of-the-art clinical trial methodologies.

Primary Markets or Conditions Targeted

Cancer patients across the Mountain West region.

Individuals at risk for hereditary cancers.

Rural and frontier communities with limited access to cancer care.

Financials and Funding

Funding History

HCI was founded with a $100 million donation from Jon M. and Karen Huntsman in 1995. Since then, the Huntsman family has contributed over $250 million to support its mission. In 2013, an additional $50 million was donated for the construction of the Primary Children's and Families' Cancer Research Center, which opened in 2017.

Total Funds Raised

Over $250 million from the Huntsman family, with additional funding from various donors and grants.

Notable Investors

The Huntsman family, including Jon M. and Karen Huntsman, have been the primary investors. HCI also receives funding from federal grants, private donors, and philanthropic organizations.

Intended Utilization of Capital

Funds are utilized for research initiatives, clinical trials, patient care facilities, community outreach programs, and educational endeavors.

Pipeline Development

Key Pipeline Candidates

HCI is involved in numerous research projects and clinical trials across various cancer types, focusing on precision oncology and innovative treatment approaches.

Stages of Clinical Trials or Product Development

HCI offers over 325 open clinical trials, including more than 45 first-in-human trials, covering all cancer types.

Target Conditions

All cancer types, with specific emphasis on melanoma, lung cancer, and cancers prevalent in rural and frontier populations.

Relevant Timelines for Anticipated Milestones

Timelines vary by study; specific milestones are detailed within individual clinical trial protocols.

Technological Platform and Innovation

Proprietary Technologies

Advanced imaging systems.

Data analytics platforms for precision medicine.

Significant Scientific Methods

Functional precision oncology using patient-derived models.

AI-driven data analysis for cancer research.

Leadership Team

Executive Profiles

Cornelia Ulrich, MS, PhD: Executive Director, Comprehensive Cancer Center; Chief Scientific Officer; Principal Investigator.

Aik Choon Tan, PhD: Senior Director of Data Science and AI.

Alana Welm, PhD: Senior Director of Basic Science.

Neeraj Agarwal, MD: Senior Director of Clinical Research.

Martin McMahon, PhD: Senior Director of Preclinical Translation.

Rachel Ceballos, PhD: Senior Director of Community Outreach and Engagement.

Theresa Werner, MD: Deputy Director, Comprehensive Cancer Center.

Tracy Onega, PhD, MS, MA, MPAS: Senior Director of Population Sciences.

Competitor Profile

Market Insights and Dynamics

The cancer care and research market is expanding, with increasing demand for innovative treatments and comprehensive care models. HCI's unique position as the only NCI-designated Comprehensive Cancer Center in the Mountain West region provides a competitive edge in serving a vast and underserved population.

Competitor Analysis

HCI's primary competitors include other NCI-designated Comprehensive Cancer Centers and regional cancer treatment facilities. However, HCI's extensive research initiatives, advanced clinical trials, and community outreach programs distinguish it in the market.

Strategic Collaborations and Partnerships

Significant Collaborations

University of Utah Health: As part of the University of Utah Health system, HCI collaborates extensively with academic and medical departments to advance research and patient care.

Affiliate Hospitals: HCI maintains partnerships with six affiliate hospitals across neighboring states to extend its reach and impact.

Operational Insights

Strategic Considerations

HCI's strategic focus on precision oncology, data science, and community outreach positions it to effectively address the evolving challenges in cancer care, particularly in rural and frontier regions.

Competitive Advantages

Exclusive NCI-designated Comprehensive Cancer Center status in the Mountain West.

Extensive network of affiliate hospitals and community clinics.

Pioneering programs like Huntsman at Home™, offering hospital-level care at home.

Strategic Opportunities and Future Directions

Strategic Roadmap

HCI plans to expand its facilities, including the new Comprehensive Cancer Center in Vineyard, Utah, to enhance access to care and research opportunities.

Future Business Directions

Enhancing AI and data analytics capabilities in research.

Expanding community outreach and education programs.

Strengthening partnerships with regional healthcare providers.

Opportunities for Expansion

The planned expansion into Vineyard, Utah, represents a significant opportunity to serve a growing population and further HCI's mission of delivering a cancer-free frontier.